Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

Instituto Nacional de Cardiologia Ignacio Chavez20 enrolled

Overview

This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Conditions

End Stage Renal Disease

Interventions

spironolactoneDRUG

25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients

PlaceboDRUG

Placebo, given daily for 6 months to Peritoneal Dialysis Patients

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 * Hospitalized for peritoneal catheter placement for peritoneal dialysis Exclusion Criteria: * Pregnancy * Hiperkalemia (K\> 5.5meq/l) * Intolerance to spironolactone

Locations (1)

Instituto Nacional de Cardiologia Ignacio Chavez

Mexico City, Mexico City, Mexico

Outcomes

Primary Outcomes

Peritoneal fibrosis

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.